R. Louis (Liège, Belgium), I. Ojanguren Arranz (Barcelona, Spain)
This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
This session includes the Best Abstract for Assembly 5 - Airway Diseases, Asthma, COPD and Chronic Cough, entitled "The Leicester Cough Questionnaire in two phase 3 trials of gefapixant in chronic cough”
The Leicester Cough Questionnaire in two phase 3 trials of gefapixant in chronic cough
S. Birring (London, United Kingdom), J. Smith (University of MancManchester, United Kingdom), A. Morice (Cottingham, United Kingdom), I. Pavord (Oxford, United Kingdom), P. Dicpinigaitis (Bronx, United States of America), L. Mcgarvey (Belfast, United Kingdom), A. Tzontcheva (Kenilworth, United States of America), Q. Li (Kenilworth, United States of America), A. Martin Nguyen (Kenilworth, United States of America), J. Schelfhout (Kenilworth, United States of America), D. Muccino (Kenilworth, United States of America), C. La Rosa (Kenilworth, United States of America)
|    |
Patient-reported chronic cough severity over 52 weeks in two phase 3 trials of gefapixant
P. Dicpinigaitis (Bronx, United States of America), S. Birring (London, United Kingdom), A. Morice (Cottingham, United Kingdom), J. Smith (Manchester, United Kingdom), I. Pavord (Oxford, United Kingdom), L. Mcgarvey (Belfast, United Kingdom), A. Tzontcheva (Kenilworth, United States of America), Q. Li (Kenilworth, United States of America), A. Martin Nguyen (Kenilworth, United States of America), J. Schelfhout (Kenilworth, United States of America), D. Muccino (Kenilworth, United States of America), C. La Rosa (Kenilworth, United States of America)
| |
Prevalence of Poor Disease Control in Patients with severe COPD according to GOLD 2021
J. Soler-Cataluña (Valencia, Spain), A. Huerta (Barcelona, Spain), P. Almagro (Terrassa, Barcelona, Spain), D. González-Segura (Barcelona, Spain), B. G Cosío (Palma de Mallorca, Balearic Islands, Spain)
| |
Real-world evidence of reported symptoms and quality of life burden associated with chronic rhinosinusitis with nasal polyposis and comorbid asthma status
B. Emmanuel (Gaithersburg, United States of America), M. Biswas (Gaithersburg, United States of America), M. Scott (Bollington, United Kingdom), M. Small (Bollington, United Kingdom), L. Lee (Bollington, United Kingdom), S. Chen (Gaithersburg, United States of America), S. Ruiz (Barcelona, Spain)
| |
The Severe Asthma Questionnaire (SAQ) - minimal clinically important difference and sensitivity to change
M. Masoli (Exeter, United Kingdom), J. Lanario (Plymouth, United Kingdom), M. Hyland (Plymouth, United Kingdom), A. Menzies-Gow (London, United Kingdom), A. Mansur (Birmingham, United Kingdom), D. Allen (Manchester, United Kingdom), D. James (Bristol, United Kingdom), G. Hayes (Plymouth, United Kingdom), J. Valderas (Exeter, United Kingdom), S. Lamb (Exeter, United Kingdom), R. Jones (Plymouth, United Kingdom)
| |
A Parent Reported Quality of Life Measure for Young Children with Primary Ciliary Dyskinesia: QOL-PCDPR
L. Behan (Southampton, United Kingdom), C. Driessens (Southampton, United Kingdom), S. Carr (London, United Kingdom), S. Dell (Vancouver, Canada), A. Harris (Southampton, United Kingdom), R. Knibb (Birmingham, United Kingdom), M. Leigh (Chapel Hill, United States of America), M. Narayanan (Leicester, United Kingdom), E. Robson (Leeds, United Kingdom), L. Schofield (Leeds, United Kingdom), J. Lucas (Southampton, United Kingdom)
| |
Treatable traits in the NOVELTY study: assessing complexity by network analysis
R. Faner (Barcelona, Spain), E. Rapsomaniki (Cambridge, United Kingdom), R. Beasley (Wellington, New Zealand), R. Hughes (Cambridge, United Kingdom), H. Müllerová (Cambridge, United Kingdom), A. Papi (Ferrara, Italy), I. Pavord (Oxford, United Kingdom), A. Agustí (Barcelona, Spain)
| |
Long-term impact of COPD on postoperative cardiorespiratory morbidity and mortality: a population cohort study
N. Diab (Toronto, Canada), A. Sankar (Toronto, Canada), J. Luo (Toronto, Canada), K. Thorpe (Toronto, Canada), D. Wijeysundera (Toronto, Canada), A. Gershon (Toronto, Canada)
| |
Is blood eosinophil count a biomarker for chronic obstructive pulmonary disease in a real-world clinical setting? Predictive property and longitudinal stability in Japanese patients.
K. Nishimura (Obu, Aichi, Japan), M. Kusunose (Obu, Aichi, Japan), R. Sanda (Obu, Aichi, Japan), M. Mori (Obu, Aichi, Japan), A. Shibayama (Obu, Aichi, Japan)
| |
Late Breaking Abstract - Blood and bronchoalveolar neutrophil signatures associate with COPD severity
T. Kapellos (Bonn, Germany), K. Bassler (Bonn, Germany), W. Fujii (Bonn, Germany), C. Nalkurthi (Newcastle, Australia), A. Frishberg (Bonn, Germany), T. Pecht (Bonn, Germany), L. Bonaguro (Bonn, Germany), E. Dudkin (Bonn, Germany), E. De Domenico (Bonn, Germany), A. Saglam (Bonn, Germany), A. Horne (Bonn, Germany), K. Händler (Bonn, Germany), M. Becker (Bonn, Germany), M. Van Uelft (Bonn, Germany), J. Hasenauer (Bonn, Germany), T. Ulas (Bonn, Germany), C. Pizarro (Bonn, Germany), P. Hansbro (Newcastle, Australia), D. Skowasch (Bonn, Germany), J. Schultze (Bonn, Germany)
| |
Discussion
| |